Biopharma 2024: Breakthrough Innovations Driving Growth
Why Crispidea Report
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Industry Analysis
 In 2024, biotech investments surged, showing growing confidence in AI’s potential to transform drug discovery, diagnostics, and biomanufacturing, leading to faster and more affordable treatments.
Emerging Trends
The AI pharmaceutical market is projected to grow from USD 1.94 billion in 2025 to USD 16.49 billion by 2034, growing at a rate of 27% annually. This is fueled by AI’s role in drug discovery, clinical trials, and personalized medicine, particularly in North America.
CrispIdea Outlook
The global biotechnology market is expected to grow USD 546 billion in 2025, reflecting an annual growth of 13%. This growth is driven by personalized medicine, biologic drugs, and advancements in AI and machine learning.
Table of Content
Executive Summary
– Key Highlights
– Market Overview
– Technological Trends
– M&A
– R&D
– Therapy Area
– Oncology
– Immunology
– Diabetes
– Cardiovascular
– CNS
– CrispIdea Outlook
– Conclusion
– Index and Stock Performance
Key Players:
– AbbVie Inc
– Sanofi SA
– Dr Reddy’s Laboratories Ltd
– Regeneron Pharmaceuticals Inc
– Eli Lilly And Co
– Moderna Inc
– GlaxoSmithKline
– Stryker Corp
– Bausch Health Companies Inc
– Zoetis Inc
– Amgen, Inc.
– Pfizer Inc.
– Tilray Brands Inc
– BioNTech SE – ADR
– Gilead Sciences, Inc.
– Biogen Inc
– Teva Pharmaceutical Industries Ltd
– Bayer
– AstraZeneca plc
– Johnson & Johnson
– Merck & Co
– Vertex Pharmaceuticals
Disclaimer
This report was produced by a member company of the Crispidea. This report is for the use of intended recipients only and may not be reproduced (in whole or in part) or delivered or transmitted to any other person without our prior written consent. By accepting this report, the recipient agrees to be bound by the terms and limitations set out herein.
